Company Description
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States.
The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.
Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases.
Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine.
The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017.
Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.
| Country | United States |
| Founded | 1995 |
| IPO Date | Apr 6, 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 405 |
| CEO | Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D. |
Contact Details
Address: 501 Canal Blvd. Richmond, California 94084 United States | |
| Phone | (510) 970-6000 |
| Website | sangamo.com |
Stock Details
| Ticker Symbol | SGMO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001001233 |
| CUSIP Number | 800677106 |
| ISIN Number | US8006771062 |
| Employer ID | 68-0359556 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D. | Chief Executive Officer, President and Director |
| Prathyusha Duraibabu CPA, M.B.A. | Senior Vice President, Chief Financial Officer and Principal Accounting Officer |
| Amy Pooler Ph.D. | Head of Research |
| Gregory Davis Ph.D. | Head of Technology |
| Aron Feingold | Head of Corporate Communications and Investor Relations Officer |
| Scott B. Willoughby | Senior Vice President, General Counsel and Corporate Secretary |
| Dr. Nathalie Dubois-Stringfellow Ph.D. | Senior Vice President and Chief Development Officer |
| Phillip Ramsey | Head of Technical Operations |
| Stephanie J. Seiler CLP | Head of Business Development and Alliance Management |
| David Ojala | Scientist II - Discovery and Translational Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 19, 2024 | ARS | Filing |
| Apr 19, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 5, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Apr 3, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 25, 2024 | 8-K | Current Report |
| Mar 25, 2024 | 424B5 | Filing |
| Mar 13, 2024 | 8-K | Current Report |
| Mar 13, 2024 | 10-K | Annual Report |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |